Axsome Therapeutics, Inc. (AXSM)

Over the past six months, Axsome Therapeutics' stock price has been impacted by several events. FDA acceptance and Priority Review for AXS-05 for Alzheimer's disease agitation, along with supportive pre-NDA feedback for AXS-12, led to a significant stock increase. The announcement of preliminary Q4 and full-year 2025 revenue resulted in an increase in the stock price. The initiation of a Phase 3 trial for AXS-14 (fibromyalgia) coincided with a stock movement. Axsome reported its earnings, missing analysts' consensus estimates for earnings per share but exceeding revenue expectations. Several financial firms updated their ratings and price targets for AXSM. Significant insider selling by the CEO and CFO was reported recently.

Axsome Therapeutics acknowledges that demand for its marketed products can be affected by seasonality, particularly for depression treatments during the summer months. Sunosi's demand in the first quarter of 2024 was negatively impacted by typical seasonality. The company also anticipates potential seasonality effects on gross-to-net discounts for Auvelity and Sunosi in Q1 2025. However, the impact of seasonality on SYMBRAVO is expected to be less pronounced during its early launch phase.

Axsome Therapeutics is a biopharmaceutical company focused on developing and delivering novel therapies for central nervous system (CNS) disorders, operating within the Health Technology sector, specifically in the Biotechnology and Medical - Biomedical industries. Its commercial product portfolio includes Auvelity for major depressive disorder and Alzheimer's disease agitation, Sunosi for excessive daytime sleepiness, and Symbravo for acute migraine, with a planned commercial launch in June 2025. Axsome also has several late-stage development programs, including AXS-05 for Alzheimer's disease agitation and smoking cessation, AXS-12 for narcolepsy, and AXS-14 for fibromyalgia.

Axsome Therapeutics develops and delivers its novel therapies for CNS disorders within the United States. The company has also expanded its market presence internationally through strategic partnerships, such as the licensing transaction with Pharmanovia to market Sunosi in Europe and certain Middle East/North Africa countries. The company's headquarters are located in New York, NY.

Axsome Therapeutics maintains a strong brand reputation, particularly within the investment community. Analyst sentiment is overwhelmingly positive, with 19 buy ratings and only one hold. The FDA's acceptance of AXS-05 for Priority Review and the approval of SYMBRAVO for acute migraine in January 2025 further contribute positively to the company's reputation.

As of March 31, 2025, institutional investors collectively held a dominant 70.94% of Axsome Therapeutics' shares, while individual investors accounted for approximately 16.48%. Major institutional owners include Vanguard Group Inc, BlackRock, Inc., Wellington Management Group Llp, Rtw Investments, Lp, Macquarie Group Ltd, Price T Rowe Associates Inc /md/, Geode Capital Management, Llc, Invesco Ltd., Antecip Capital, L.L.C., State Street Global Advisors, Inc., and Nomura Investment Management Business Trust. The founder, Chief Executive Officer, and Chairman of the Board of Directors is Herriot Tabuteau, MD.